PMID- 32099697
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2090-6560 (Print)
IS  - 2090-6579 (Electronic)
IS  - 2090-6579 (Linking)
VI  - 2020
DP  - 2020
TI  - Successful Treatment of Pediatric Refractory/Relapsed AML with 
      KIR-Ligand-Mismatched Cord Blood Transplant after FLAG-IDA Reinduction Therapy 
      with or without the GO Regimen.
PG  - 1378056
LID - 10.1155/2020/1378056 [doi]
LID - 1378056
AB  - Prognosis in pediatric patients with refractory/relapsed acute myeloid leukemia 
      (AML) is grim, and there is no standard treatment for such patients. Combined 
      treatment with intensive chemotherapy and gemtuzumab ozogamicin (GO), a 
      monoclonal anti-CD33 antibody conjugated with calicheamicin, is useful as 
      reinduction therapy in refractory/relapsed AML. Here, we describe three cases of 
      pediatric refractory/relapsed AML that were successfully managed with FLAG-IDA 
      (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), 
      with or without GO, as reinduction therapy before a KIR-ligand-mismatched cord 
      blood transplant. This strategy relies on the fact that killer cell 
      immunoglobulin-like receptors (KIR) on cord blood natural killer (NK) cells 
      recognize human leukocyte antigen (HLA) class I alleles, and that donor 
      KIR-ligand incompatibility may be associated with lower incidence of relapse and 
      improved survival in AML, as cells that lack these inhibitory HLA ligands can 
      activate NK cells. All three patients are currently alive and have been 
      disease-free for 24-65 months, although one patient developed severe sinusoidal 
      obstructive syndrome (SOS). Thus, our strategy can result in excellent outcomes 
      in pediatric patients with refractory/relapsed AML.
CI  - Copyright (c) 2020 Daisuke Toyama et al.
FAU - Toyama, Daisuke
AU  - Toyama D
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Matsuno, Ryosuke
AU  - Matsuno R
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Sugishita, Yumiko
AU  - Sugishita Y
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Kaneko, Ryota
AU  - Kaneko R
AUID- ORCID: 0000-0001-8158-6338
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Okamoto, Naoko
AU  - Okamoto N
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Koganesawa, Masaya
AU  - Koganesawa M
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Fujita, Sachio
AU  - Fujita S
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Akiyama, Kosuke
AU  - Akiyama K
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Isoyama, Keiichi
AU  - Isoyama K
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
FAU - Yamamoto, Shohei
AU  - Yamamoto S
AUID- ORCID: 0000-0003-1582-7062
AD  - Department of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
LA  - eng
PT  - Case Reports
DEP - 20200212
PL  - United States
TA  - Case Rep Hematol
JT  - Case reports in hematology
JID - 101576456
PMC - PMC7037524
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2020/02/27 06:00
MHDA- 2020/02/27 06:01
PMCR- 2020/02/12
CRDT- 2020/02/27 06:00
PHST- 2019/09/19 00:00 [received]
PHST- 2020/01/11 00:00 [revised]
PHST- 2020/01/25 00:00 [accepted]
PHST- 2020/02/27 06:00 [entrez]
PHST- 2020/02/27 06:00 [pubmed]
PHST- 2020/02/27 06:01 [medline]
PHST- 2020/02/12 00:00 [pmc-release]
AID - 10.1155/2020/1378056 [doi]
PST - epublish
SO  - Case Rep Hematol. 2020 Feb 12;2020:1378056. doi: 10.1155/2020/1378056. 
      eCollection 2020.